- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00781339
Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients
A Phase IIa Open Label Study to Evaluate the Safety and Antimicrobial Effects of NVC-422 on Bacteriuria in Chronically Catheterized Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Catheter-associated urinary tract infection (CAUTI) is a major healthcare problem in the U.S., accounting for approximately 40% of all hospital acquired infections. Microorganisms can colonize the catheter extraluminally or intraluminally, and are often protected in a biofilm environment. Nearly all patients catherized for 30 days or longer will develop bacteriuria, or the presence of bacteria in normally sterile urine. Ten to twenty percent of these patients will develop a symptomatic CAUTI. In a further 1-4%, the infection will spread into the kidneys or bloodstream, leading to potentially lethal bacteremia.
Currently, there is no bladder irrigation solution that can reduce or eliminate CAUTI. A bladder instillation solution that can keep the bladder and catheter substantially free of bacteria and biofilm is expected to provide a practical and cost-effective means of minimizing CAUTIs.
NVC-422 is a topical, non-antibiotic, fast acting, broad spectrum anti-microbial, which exhibits potential for the rapid decolonization of a range of urologic pathogens, including Escherichia Coli (E. coli), Enterococcus spp., P. mirabilis and others. In vitro studies with NVC-422 have also shown that it is capable of penetrating a biofilm and effectively killing the contained microbes.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Michael E. Debakey V.A. Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients or their guardians are willing and able to provide informed consent
- Age > 18 years
- Condition requiring chronic transurethral catheterization for at least 1 month prior to enrollment
- Indwelling transurethral catheter not scheduled for exchange for at least 1 week from first treatment
- Documented asymptomatic bacteriuria as defined in the protocol
- Vital signs within the following limits: blood pressure 90 to 160 mm Hg systolic and 50 to100 mm Hg diastolic, pulse rate 45 to 100 bpm, respiratory rate 8 to 24 respirations per minute, oral body temperature 35.5ºC to 38.0ºC
- Screening must occur within 14 days of enrollment into the study
Exclusion Criteria:
- Unwillingness/inability to fulfill the requirements of the study
- History of hepatitis B or C, HIV, AIDS, or other immunodeficiency disease
- Systemic antibiotics within 7 days of enrollment
- Any condition that, in the opinion of the principal investigator, would make the subject unsuitable for the study or place the subject at additional risk.
- Any investigational drug or investigational device within 30 days of enrollment in the study
- Women who are pregnant or lactating; or of child-bearing potential unless using highly effective birth control method for 1 month prior to and during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active
|
0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the safety and antimicrobial effect (and its duration) of NVC-422 in urine following bladder instillation in chronically catheterized subjects with bacteriuria
Time Frame: 7-10 days
|
7-10 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Assess urine concentration of NVC-422 and its primary metabolite (2,2-DMT) following bladder instillation
Time Frame: 1-7 days
|
1-7 days
|
Assess plasma concentration of NVC-422 and its primary metabolite (2,2-DMT) following bladder instillation
Time Frame: 1-7 days
|
1-7 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rabih O. Darouiche, M.D., Baylor College of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL0803
- H-23765
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asymptomatic Bacteriuria
-
Kendall Healthcare Group, Ltd.CompletedAsymptomatic Bacteriuria | Asymptomatic PyuriaUnited States
-
Loyola UniversityRecruitingUrinary Tract Infections | Asymptomatic BacteriuriaUnited States
-
Military Institute of Medicine, PolandUnknownAsymptomatic Bacteriuria | Antimicrobial ProphylaxisPoland
-
Jorge Andres Ramos CastanedaUnknownAsymptomatic Bacteriuria | Antibiotic ProphylaxisColombia
-
Mount Sinai Hospital, CanadaCompletedUrinary Tract Infections | Asymptomatic BacteriuriaCanada
-
University of California, IrvineCompletedAsymptomatic BacteriuriaUnited States
-
Centenario Hospital Miguel HidalgoCompletedKidney Transplant Infection | Asymptomatic BacteriuriaMexico
-
St. Luke's Hospital, PennsylvaniaUnknownAsymptomatic Bacteriuria in Pregnancy
-
Saint Joseph Mercy Health SystemTerminatedBacteriuria (Asymptomatic) in PregnancyUnited States
-
VA Office of Research and DevelopmentCompletedAsymptomatic Bacteriuria | Infection Due to Indwelling Urinary CatheterUnited States
Clinical Trials on sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate
-
NovaBay Pharmaceuticals, Inc.Novum Pharmaceutical Research Services; International Dermatology Research,...Completed
-
University of UlmCompletedChronic Renal Insufficiency | Serum Creatinine Concentration | Contrast Media ExpositionGermany
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Active, not recruitingHematopoietic and Lymphoid Cell NeoplasmUnited States
-
Mylan Pharmaceuticals IncCompletedHealthyUnited States
-
Texas A&M UniversityNutraboltCompletedDietary Modification
-
Sanofi Pasteur, a Sanofi CompanyImmune DesignTerminated
-
Nobias Therapeutics, Inc.Completed22q11 Deletion SyndromeUnited States, Canada
-
Laura CavalloneCompletedHyperalgesia | AllodyniaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Cancer Institute (NCI)CompletedFollicular Lymphoma | Myeloid Leukemia | Polycythemia Vera | Hodgkin Lymphoma | Myelofibrosis | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Chronic Lymphocytic Leukemia | Secondary Acute Myeloid Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Refractory... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnRecurrent Acute Myeloid LeukemiaUnited States